- Novavax is expected to be hit the Australian markets in January 2022. It is clinically proven that Novavax is 90% effective against symptomatic infection.
- Although Novavax is different from the previous vaccines but share similarities in terms of side effects.
A new brand in the COVID-19 vaccine world – Novavax – is expected to be available in Australia soon as the country continues to fight the new Omicron variant.
Recently approved by the European Union, Novavax or NVX-CoV2373 is a new protein-based vaccine developed by the biotech company Novavax.
As per media reports, the Australian Health Minister -Greg Hunt said that the new Novavax vaccine will likely be available in January 2022.
Novavax has been proved to be highly effective against COVID-19 as the clinical trials have demonstrated that it is 90% effective against symptomatic infection and 100% effective towards moderate to severe diseases. However, with limited data, its efficacy against the Omicron variant is yet to be proved.
RELATED READ - Can current COVID-19 vaccines fight Omicron?
As per media reports, Novavax’s CEO Stanley Erick has stated that, although there’s limited data, the company believes that this vaccine will still provide strong protection from Omicron. Additionally, the company is currently making a new vaccine for the variant.
Novavax differs from Pfizer, AstraZeneca and Moderna, but have similar side effects, where injection site tenderness, headache, muscle pain etc., are some most common symptoms. Once available, Novavax will be administered in two doses in three weeks intervals.